

Editorial

News in this issue

This issue of the Forum for Nordic Dermato-venereology brings good news.

Dr. Steen Lisby presents an educational review on new biological treatments of psoriasis, and Dr. Robert Gniadecki addresses a difficult issue how to position this new treatment in clinical routine treatment of psoriasis, a disease we know severely affects quality of life. There are pros and cons.

A few weeks ago two biologicals (efaluzimab and etanercept) were granted approval by the European drug agency in London (EMA) specifically on the indication moderate to severe psoriasis, when special treatment is needed. It is important that we can offer every sufferer the best treatment of his particular case and that we as a specialty have access to and master this new generation of therapies. It would be sad if we remained in the off-label grey zone. Positioning of new therapies takes time, and practical experience and discussion among colleagues will go hand in hand before the position is known. It is likely that treatment will be highly individual, i.e. continuous treatment, treatment at exacerbation only, part of rotational regimen, combination treatment with methotrexate or other conventional treatment, etc. The Forum for Nordic Dermato-Venereology invites contributions and debate articles about the new biological treatments.

New Editors

Dr. *Karsten Fogh*, who has served as the Danish national editor since 2002 has asked to be relieved from this task.

The new national editor for Denmark will be Dr *Robert Gniadecki*. Robert Gniadecki's special interests are cell biology and the skin, and cutaneous oncology.

Dr *Östen Hägermark* has served as the Swedish co-editor since 1999 and has now decided to end this work with us. He will be succeeded by Dr *Bernt Lindelöf*, whose main interest is dermatological cancer epidemiology.

Dr *Gregor Jemec* has served as the CME editor since the introduction of this section. Other tasks have forced him to end his work with us. His successor is Dr *Tomas Norman Dam* who took over as the CME Editor from the 1st issue of this year. Tomas Dam's special interest is inflammation and immunology of the skin.

We are most grateful for all efforts for our journal made by Karsten Fogh, Östen Hägermark and Gregor Jemec. Thank you! We also would like to welcome the new Editors Robert Gniadecki, Bernt Lindelöf and Tomas Dam and are sure they will further increase the good reputation of our journal.

Educational Reviews

In this issue we introduce educational reviews, which are short and personal reviews on any aspect of the specialty different from the traditional literature review. They will be easy to read and address essential points. We invite our readers to contribute. A guide is available from the editorial office.



August 2004

Jørgen Serup


chief-editor



Karsten Fogh
has left the Forum Board



Östen Hägermark
has left the Forum Board



Gregor Jemec
has left the Forum Board



Robert Gniadecki
is the new Danish editor



Bernt Lindelöf
is the new Swedish co-editor



Tomas Norman Dam
is the new CME editor